tiprankstipranks
BICO Group AB Class B (DE:49Z)
FRANKFURT:49Z

BICO Group AB Class B Stock Analysis & Ratings

0 Followers

49Z Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€4.01
Volume2.31K
Average Volume (3M)6.89K
Market CapN/A
Enterprise ValueN/A
P/E RatioN/A
Beta-1.42
Next EarningsAug 24, 2022
EPS Forecast-€0.14
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart ScoreN/A
EPS (TTM)N/A
Shares Outstanding64,086,269
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume24,994
30 Day Avg. Volume6,895
P/B Ratio0.30
P/S Ratio0.15
P/CF RatioN/A
P/FCF Ratio-0.90
Total Debt€43.54M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
AlphaN/A
Number of Analyst Covering0


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

49Z FAQ

What was BICO Group AB Class B’s price range in the past 12 months?
Currently, no data Available
What is BICO Group AB Class B’s market cap?
Currently, no data Available
What is BICO Group AB Class B’s price target?
Currently, no data Available
What do analysts say about BICO Group AB Class B?
Not enough analysts have published a price target to provide an average price target.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Aug 24, 2022 which is in 5 days.
    How were BICO Group AB Class B’s earnings last quarter?
    BICO Group AB Class B released its earnings results on May 18, 2022. The company reported -€0.066 earnings per share for the quarter, beating the consensus estimate of -€0.154 by €0.088.
      Is BICO Group AB Class B overvalued?
      According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does BICO Group AB Class B pay dividends?
        BICO Group AB Class B does not currently pay dividends.
        What is BICO Group AB Class B’s EPS estimate?
        BICO Group AB Class B’s EPS estimate is -€0.14.
          How many shares outstanding does BICO Group AB Class B have?
          Currently, no data Available
          What happened to BICO Group AB Class B’s price movement after its last earnings report?
          BICO Group AB Class B reported an EPS of -€0.066 in its last earnings report, beating expectations of -€0.154. Following the earnings report the stock price went down -2.961%.
            Which hedge fund is a major shareholder of BICO Group AB Class B?
            Currently, no hedge funds are holding shares in DE:49Z

            ---

            BICO Group AB Class B Stock Analysis

            Smart ScoreNot Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10
            N/A

            Analyst Forecast

            N/A
            Currently Not Enough Data Available

            Blogger Sentiment

            N/A
            Currently Not Enough Data Available

            Insider Transactions

            N/A
            Currently Not Enough Data Available

            News Sentiment

            N/A
            Currently Not Enough Data Available

            Technicals

            SMA
            Negative
            20 days / 200 days
            Momentum
            -93.61%
            12-Months-Change

            Fundamentals

            Return on Equity
            -4.26%
            Trailing 12-Months
            Asset Growth
            52.27%
            Trailing 12-Months
            This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
            Learn more about TipRanks Smart Score

            Company Description

            BICO Group AB Class B

            CELLINK AB is engaged in the development and commercialization of bioprinting technologies. Its products allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products and for clinical applications. The company's technology is used to print tissues such as liver, cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments.

            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Olink Holding

            Popular Stocks

            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis